{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:21:23Z","timestamp":1790014883874,"version":"4.0.1"},"reference-count":32,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2011,4,22]],"date-time":"2011-04-22T00:00:00Z","timestamp":1303430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>IncobotulinumtoxinA (NT 201, Xeomin) is a highly purified botulinum neurotoxin type A formulation, free from complexing proteins. A randomized, placebo\u2010controlled, double\u2010blind trial of efficacy and safety compared incobotulinumtoxinA (up to 50 U per eye) to placebo administered in a single treatment session to patients with blepharospasm. All patients had documented satisfactory response to 2 previous treatments with botulinum neurotoxin type A other than incobotulinumtoxinA and had Jankovic Rating Scale severity subscores \u2265 2. Patients (n = 109) were randomized in a 2:1 ratio to incobotulinumtoxinA or placebo and followed up to 20 weeks; 94% completed the study. A significant difference was observed in the primary efficacy variable (change in Jankovic Rating Scale severity subscore rated by an independent rater 6 weeks following treatment), favoring incobotulinumtoxinA by 1.0 point (95% CI [0.5\u20131.4]; <jats:italic>P<\/jats:italic> &lt; .001). Functional impairment, as measured by the Blepharospasm Disability Index, improved by 0.5 points (95% CI [0.2\u20130.7]; <jats:italic>P<\/jats:italic> = .002) compared with placebo. There was a strong correlation between the 2 scale scores. In addition, all secondary outcome measures favored incobotulinumtoxinA. Patients rated the mean therapeutic effect of incobotulinumtoxinA significantly better than placebo (<jats:italic>P<\/jats:italic> &lt; .001). Adverse events were reported in 70.3% of incobotulinumtoxinA patients and 58.8% of placebo patients. Eyelid ptosis (18.9% vs 5.9%), dry eye (18.9% vs 11.8%), and dry mouth (14.9% vs 2.9%) occurred most frequently. Tolerability was rated good\/very good by 91.9% of incobotulinumtoxinA versus in 85.2% of placebo patients. In conclusion, incobotulinumtoxinA was well tolerated and was associated with statistically significant and clinically relevant reductions in blepharospasm severity and functional impairment. \u00a9 2011 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.23658","type":"journal-article","created":{"date-parts":[[2011,4,22]],"date-time":"2011-04-22T10:30:33Z","timestamp":1303468233000},"page":"1521-1528","source":"Crossref","is-referenced-by-count":78,"title":["Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm\u2014A randomized trial"],"prefix":"10.1002","volume":"26","author":[{"given":"Joseph","family":"Jankovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Comella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Hanschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Grafe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,4,22]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000327601.46315.85"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1275"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004150070094"},{"key":"e_1_2_7_5_2","first-page":"371","article-title":"Blepharospasm: demographic and clinical survey of 250 patients","volume":"16","author":"Jankovic J","year":"1984","journal-title":"Ann Ophthalmol"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.60.2.204"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.51.6.767"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000142035.26034.C2"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2001.00109.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2008.09.023"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000311389.26145.95"},{"key":"e_1_2_7_12_2","first-page":"CD004900","article-title":"Botulinum toxin type A therapy for blepharospasm","volume":"2","author":"Costa J","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007813"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01441.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210301300401"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-009-9023-3"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2009.192"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7228.161"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004150070100"},{"key":"e_1_2_7_20_2","unstructured":"United States Adopted Names Council. Available at:http:\/\/www.ama\u2010assn.org\/ama\/pub\/about\u2010ama\/our\u2010people\/coalitions\u2010consortiums\/united\u2010states\u2010adopted\u2010names\u2010council\/adopted\u2010names.shtml. Accessed November 5 2010."},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2009.03.010"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767050-00003"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-004-0234-8"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000240951.18821.50"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000163767.99354.C3"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-005-0323-3"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22368"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(00)00146-9"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1997.6580"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2007.11.003"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.034702"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.28421-0"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2009.01.017"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.23658","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.23658","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.23658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:38:03Z","timestamp":1760960283000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.23658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,22]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1002\/mds.23658"],"URL":"https:\/\/doi.org\/10.1002\/mds.23658","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,22]]}}}